Skip to main content
SpringerLink
Log in

Anxiolytika

  • Chapter
Kompendium der Psychiatrischen Pharmakotherapie

  • 5101 Accesses

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Anxiolytika im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben. Außerdem werden Substanzen besprochen, deren primäre Indikation außerhalb der Angststörungen liegt, die aber auch bei diesen wirksam sind.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Baldwin DS, den Boer JA, Lyndon G et al (2015) Efficacy and safety of pregabalin in generalised anxiety disorder: a critical review of the literature. J Psychopharmacol 29(10): 1047–1060

    Google Scholar 

  • Billioti de Gage S, Pariente A, Bégaud B (2015) Is there really a link between benzodiazepine use and the risk of dementia? Expert Opin Drug Saf 14(5): 733–747

    Google Scholar 

  • Gray SL, Dublin S, Onchee Yu et al (2016) Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ 352: i90

    Google Scholar 

  • Hofmann SG, Mundy EA, Curtiss J (2015) Neuroenhancement of exposure therapy in anxiety disorders. AIMS Neurosci 2(3): 123–138

    Google Scholar 

  • Hui Poon S, Sim K, Baldessarini RJ (2015) Pharmacological approaches for treatment-resistant bipolar disorder. Curr Neuropharmacol 13: 592–604

    Google Scholar 

  • Kasper S, Gastpar M, Müller WE et al (2014) Lavender oil preparation silexan is effective in generalized anxiety disorder – a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol 23: 1–11

    Google Scholar 

  • Liebowitz MR, Salman E, Nicolini H et al (2014) Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder. Am J Psychiatry 171(6): 675–682

    Google Scholar 

  • Lüddens H (2012) Anxiolytika und Hypnotika. In: Gründer G, Benkert O (Hrsg) Handbuch der Psychopharmakotherapie, 2. Aufl. Springer, Berlin Heidelberg New York, S 695–712

    Google Scholar 

  • Meyer B, Yuen KS, Ertl M et al (2015) Neural mechanisms of placebo response. J Neursci 35(19): 7365–7373

    Google Scholar 

  • Olfson M, King M, Schoenbaum M (2015) Benzodiazepine use in the United States. JAMA Psychiatry 72(2): 136–142

    Google Scholar 

  • Pollack MH, van Ameringen M, Simon NM et al (2014) A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry 171: 44–53

    Google Scholar 

  • Sakakibara M, Igarashi A, Takase Y et al (2015) Effects of prescription drug reduction on quality of life in community-dwelling patients with dementia. J Pharm Pharm Sci18(5): 705–712

    Google Scholar 

  • Salih H, Anghelescu I, Kezic I et al (2015) Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomized, double-blind phase-I studies. J Psychopharmacol 29(4): 414–425

    Google Scholar 

  • Schjerning O, Rosenzweig M, Pottegard A et al (2016) Abuse potential of pregabalin: a systematic review. CNS Drugs 30(1): 9–25

    Google Scholar 

  • Soeter M, Kindt M (2015) An abrupt transformation of phobic behavior after a post-retrieval amnesic agent. Biol Psychiatry 78(12): 880–886

    Google Scholar 

  • Stein MB, Sareen J (2015) CLINICAL PRACTICE. Generalized anxiety disorder. N Engl J Med 373(21): 2059–2068

    Google Scholar 

  • Temmingh H, Stein DJ (2015) Anxiety in patients with schizophrenia: epidemiology and management. CNS Drugs 29(10): 819–832

    Google Scholar 

  • Weber SR, Wehr AM, Duchemin AM (2016) Prevalence of antipsychotic prescriptions among patients with anxiety disorders treated in inpatient and outpatient psychiatric settings. J Affect Disord 191: 292–299

    Google Scholar 

  • Yaffe K, Boustani M (2014) Benzodiazepines and risk of Alzheimer’s disease. BMJ 349: g5312

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Liebenburg

    Prof. Dr. med. I. Anghelescu

  2. Mainz

    Prof. Dr. med. O. Benkert

Authors
  1. Prof. Dr. med. I. Anghelescu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. O. Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Mainz

    Otto Benkert

  2. München

    Hanns Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Anghelescu, I., Benkert, O. (2017). Anxiolytika. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-50333-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-50333-1_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-50332-4

  • Online ISBN: 978-3-662-50333-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation